Topic: HBK-15

Mental disorders, including depression and anxiety, are a major health concern worldwide, affecting more than 540 million people globally. Although there are treatments available to help with various symptoms, cognitive deficits, particularly impaired executive functions, are often not addressed. In this study, we aim to investigate the effectiveness of HBK-15, a multimodal compound known for its rapid antidepressant-like effect, in reducing cognitive flexibility deficits in mice.We used male Balb/c mice. To assess the effect on cognitive flexibility, we used touchscreen-based two-choice pairw

Depression affects 30 million people worldwide, and women are diagnosed with this condition nearly twice as often as men. Cognitive impairments that develop during depression contribute to poor therapeutic outcomes and reduced quality of life. Recognizing the significance of sex as a variable in depression research, we investigated the procognitive properties of a multimodal compound- HBK-15 in female mice using two models of cognitive impairments: induced by NMDA receptor blockade or stress. We employed the object recognition test to assess intermediate recognition memory. We used MK-801 (NMD

Depression, affecting 280 million people worldwide, is marked by a significant treatment gap. Current therapies with delayed onset of action fail to alleviate the symptoms in almost half of patients, often neglecting the cognitive deficits. This highlights the critical need for fast-acting antidepressants with memory-enhancing properties. HBK-15, a multimodal compound, previously demonstrated antidepressant-, anxiolytic-like and antiamnesic effects in rodents. Our study aimed to explore HBK-15's potential in reversing stress-induced behavioral abnormalities and elucidating its underlying mecha